Immunogenicity of RSVPreF3 Vaccine in Immunocompromised Persons (NCT07050732)
Immunogenicity and Safety of Multiple-Dose Adjuvanted RSVPreF3 (Arexvy®) Vaccination Among Immunocompromised Persons
🩺 Plain-English Summary (8th-Grade Level)
This clinical trial is being done to learn more about how well a vaccine (Arexvy®) for respiratory syncytial virus, also known as RSV, works in people with weakened immune systems. The main questions it aims to answer are: * Does 1 or 2 doses of Arexvy work better in people with weakened immune systems? * What medical problems do participants have after receiving Arexvy? Participants with weakened immune systems will: * Receive 3 study vaccines over the course of 1 year * Keep a diary of symptoms for 7 days after each vaccine * Have 3 in-person follow up study visits for checkups and tests over the course of 1.5 years * Have 6 phone follow up study visits over the course of 1.5 years
Who can join: Review the eligibility criteria below.
Location: Johns Hopkins University — Baltimore, Maryland
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- Johns Hopkins University — Baltimore, Maryland
📞 Contact the Study Coordinator
Phone: (443) 287-1964
Email: jbaddle1@jh.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Respiratory Syncytial Virus (RSV)
- Real-World Effectiveness of RSV Vaccines Among Adults Using Target Trial Emulation in Epic Cosmos — New York, New York
- A Phase 1 Study to Evaluate JCXH-108, an mRNA-based Vaccine Against RSV — Jupiter, Florida
- Evaluating ABRYSVO Maternal Vaccine Effectiveness Among Infants — New York, New York
- Systems Biological Analysis of Immune Responses to RSV Vaccine — Decatur, Georgia
- A Study to Learn About Revaccination With a Vaccine Called RSVpreF in Immunocompromised Adults — Rochester, New York
- RSV Vaccine Pregnancy Registry — Wilmington, North Carolina
Explore by condition: All Respiratory Syncytial Virus (RSV) clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.